Memantine in moderate-to-severe Alzheimer's disease.

Reisberg B, Doody R, Stoffler A, 
Schmitt F, Ferris S, Mobius HJ

 Memantine Study Group.
Department of Psychiatry, 
New York University School of Medicine, 
New York 10016, USA. barry.reisberg@med.nyu.edu
N Engl J Med 2003 Apr 3;348(14):1333-41

Abstract

BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. 

METHODS: Patients with moderate-to-severe Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev). The secondary efficacy end points included the Severe Impairment Battery and other measures of cognition, function, and behavior. Treatment differences between base line and the end point were assessed. Missing observations were imputed by using the most recent previous observation (the last observation carried forward). The results were also analyzed with only the observed values included, without replacing the missing values (observed-cases analysis). 

RESULTS: Two hundred fifty-two patients (67 percent women; mean age, 76 years) from 32 U.S. centers were enrolled. Of these, 181 (72 percent) completed the study and were evaluated at week 28. Seventy-one patients discontinued treatment prematurely (42 taking placebo and 29 taking memantine). Patients receiving memantine had a better outcome than those receiving placebo, according to the results of the CIBIC-Plus (P=0.06 with the last observation carried forward, P=0.03 for observed cases), the ADCS-ADLsev (P=0.02 with the last observation carried forward, P=0.003 for observed cases), and the Severe Impairment Battery (P<0.001 with the last observation carried forward, P=0.002 for observed cases). Memantine was not associated with a significant frequency of adverse events. 

CONCLUSIONS: Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.

 | order |

Galantamine Alzheimer's articles      www.AlzheimersTreatments.com

Galantamine  fights Alzheimer's
   In the 1950s, a Bulgarian pharmacologist noticed that local villagers rubbed their foreheads with the snowdrop plant to ease nerve pain. Further investigation led to the isolation of the snowdrop extract galantamine  continue

Galantamine: why galantamine is the best agent for restoring memory
   Galantamine has several advantages over donepezil (Aricept®) and rivastigmine (Exelon®)    continue

Galantamine: can sharpen your mental edge
   Galantamine's positive results in slowing the progression of Alzheimer's disease may be due  continue

Galantamine: helps save Memory
   Galantamine is used in treating Alzheimer's disease, because of its ability   continue

Galantamine: beats Prescription Drugs for combating Mental Decline
  Galantamine is different from donepezil (Aricept®) and rivastigmine (Exelon®) in one very important way, galantamine has the unique ability to increase the receptiveness of nicotinic receptors to acetylcholine  continue

Galantamine: opens the channels of your Memory
   The secret of galantamine's success lies in your brain's nicotinic receptors.  continue

Galantamine:  Protect Brain Function by Enhancing Neurotransmission
   Galantamine has been found to be effective in treating  Alzheimer's disease   continue

Galantamine: Boost Memory
   Galantamine achieves the same effect as drugs such as Aricept or tacrine, but has additional benefits   continue

Galantamine protects Brain funtion
   The primary objective with Alzheimer's is to enhance neurotransmission so as to retain memory  continue
    
Galantamine: food for Mind & Body
   Galantamine is a flower extract that improves memory and perhaps even helps with impotence  continue

Galantamine  may help stave off Dementia
   Dementia is a progressive loss of memory accompanied by significant  continue

Galantamine: Memory Enhancement
   Alzheimer's patients  suffer sharp declines in their brain levels of acetylcholine. Galantamine    continue

Galantamine rescues Brain Cells
   According to a study of 653 Alzheimer's disease patients published in the British Medical Journal, the herbal supplement galantamine "appears to slow the progression of the neurodegenerative condition"  continue

Galantamine: the Old Become Young
   As we age, it becomes harder to learn new things. One explanation is the deterioration of the brain's continue

Galantamine: What's Old with Acetylcholine is New to Us
   Acetylcholine deficiency is characteristic of Alzheimer's disease. The primary treatment is administration of agents like galantamine, an extract from the snowdrop and daffodil plants  continue